Parainfluenza Clinical Trials

• Participants who have new onset or worsening (if present chronically) of at least 1 of the following signs and/or symptoms consistent with a viral acute respiratory infection within 72 hours prior to randomization: fever, nasal congestion, nasal discharge, sore throat, cough, sputum production, shortness of breath, or wheezing.

• Participants diagnosed with RSV infection preferably using a rapid polymerase chain reaction (PCR) or other molecular-based diagnostic assay.

• Has at least 1 of the following risk factors for severe RSV disease:

‣ ≥ 75 years of age;

⁃ Chronic lung disease that is symptomatic and requiring chronic treatment; and

⁃ Chronic cardiovascular disease that is symptomatic and requiring chronic treatment.

• With the exception of the RSV disease, medically stable on the basis of medical history, physical examination, vital signs, and 12-lead electrocardiogram (ECG) performed at screening.